Randomized DSEE-CRC trial will test tumoroid-guided therapy in refractory metastatic colorectal cancer
The DSEE-CRC trial will randomize patients with chemotherapy-refractory metastatic colorectal cancer to tumoroid-guided therapy or standard trifluridine-tipiracil and bevacizumab.
